Tourmaline Bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Tourmaline Bio and buy or sell other stocks, ETFs, and their options commission-free!About TRML
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006.
CEOSandeep C. Kulkarni, MD
CEOSandeep C. Kulkarni, MD
Employees74
Employees74
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2021
Founded2021
Employees74
Employees74
TRML Key Statistics
Market cap1.23B
Market cap1.23B
Price-Earnings ratio-13.97
Price-Earnings ratio-13.97
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$48.27
52 Week high$48.27
52 Week low$11.56
52 Week low$11.56
Stock Snapshot
Tourmaline Bio(TRML) stock is priced at $47.98, giving the company a market capitalization of 1.23B. It carries a P/E multiple of -13.97.
On 2025-12-07, Tourmaline Bio(TRML) stock opened at —, reached a high of —, and a low of —.
The Tourmaline Bio(TRML)'s current trading volume is 0.
In the last year, Tourmaline Bio(TRML) shares hit a 52-week high of $48.27 and a 52-week low of $11.56.
In the last year, Tourmaline Bio(TRML) shares hit a 52-week high of $48.27 and a 52-week low of $11.56.
People also own
Based on the portfolios of people who own TRML. This list is generated using Robinhood data, and it’s not a recommendation.